Effects of Mycotoxins

Mycotoxins are secondary metabolites produced by fungi that grow on crops in the field or during storage time. The major fungi families that cause problems in animals and humans are Aspergillus, Fusarium, and Penicillium.

Mycotoxins give rise to many different pathological effects in animals and humans such as toxicity in the liver and kidney, defects of central nervous system and estrogenic responses. These pathologies lead to lower animal performance and productivity.

In total, more than 500 mycotoxins have been identified, and five of them, Aflatoxin (AFLA), Deoxynivalenol (DON), Zearalenone (ZEA), Fumonisin (FUM) and Ochratoxin (OTA) were found to cause significant economic loss in the agriculture industry. In fact, the Food and Agriculture Organization (FAO) of the United Nations estimated that 25% of crops across the globe are contaminated by mycotoxins yearly (CX/CF 12/6/14).

It is a threat for mycotoxins to be present in the feed ingredients and finished feed, as they can have an adverse effect on the health of livestock which would indirectly impact the food chain. Thus, effective prevention and control measures for the high occurrences of mycotoxins must be implemented to reduce the risk of increasing mycotoxin deposition in the field and during storage.

Mold inhibitors can be used to mitigate this risk by preventing mold growth during the storage of feed and feed ingredients but are ineffective against mycotoxins. The concurrent addition of a broad spectrum mycotoxin binder provides a comprehensive solution in reducing the toxicity risk of mycotoxins.


In vivo excretion studies

 

In vivo Excretion Studies

The most precise method to evaluate the in vivo efficacy of a mycotoxin binder is to conduct a balance study and determine excretion/absorption of the toxin in the feces.

TOXFIN™ Dry has been shown to promote the excretion of different mycotoxins such as Aflatoxin B1, Ochratoxin A, Trichothecenes, and Citrinin. The excretion of mycotoxins has doubled or tripled with the addition of TOXFIN™ Dry compared to the untreated group.

 

 

In vivo performance studies

 

In vivo Performance Studies

TOXFIN™ reduces the bioavailability of mycotoxins. Therefore the negative effects of mycotoxins on the animals’ health and performance are reduced.

Many studies have shown that the addition of TOXFIN™ Dry to contaminated diets results in full recovery of the liver and kidney weights.

Visual evaluation of the liver confirmed that TOXFIN™ Dry has successfully eliminated the negative effects of the mycotoxins.

TOXFIN™ Dry restores the vaccination response when broilers are challenged with mycotoxins. The inclusion of TOXFIN™ Dry leveled the haemagglutination inhibition (HI) titre to the control level.

 

Effects of TOXFIN™ on liver health HI titre values against Newcastle Disease antigen Conclusion

TOXFIN™ is an optimized and proprietary formula of purified and activated adsorbents that protects against a wide range of mycotoxins. By binding mycotoxins in the gastrointestinal tract, it reduces their absorption and promotes their excretion from the animals’ body.

Backed-up by in vitro and in vivo research, TOXFIN™ is a proven technology that is compatible with feed processing and antimicrobial feeding programs, ensuring consistent results without side effects.

Have a Question About TOXFIN?